High blood pressure (hypertension) often results from modern day lifestyle characterized by low physical activity, poor eating that result in excess weight and various other unhealthy habits. In blood pressure treatment, the proper dose of a drug is of critical importance. A recent study set out to determine the optimal dose of the egg protein hydrolysate NTW-03 to correct high blood pressure.
Millions of people suffer life-threatening conditions and disabilities due to untreated blood pressure (BP) issues. In the treatment of high blood pressure, the most common class of drugs used is the angiotensin converting enzyme (ACE) inhibitors. When angiotensin-I is converted to angiotensin-II by ACE, it increases the level of aldosterone which in turns causes vasoconstriction resulting in high blood pressure. The egg protein hydrolysate NTW-03 was recently found to inhibit the ACE in fat rats. Previous studies have shown that the dose of drug is critical in the management of high BP. However, no study had been done to determine the optimal dose of NTW-03 for treating high BP in humans.
Researchers at Maastricht University in the Netherlands conducted a dose-finding study to determine the optimal dose of NTW-03 for treating human subjects . The study included a total of 92 human subjects; 29 with normal BP, 34 with normal-high BP and 29 with mild hypertension. The subjects selected had no major health issues, and pregnant or lactating women were excluded. BP of the subjects was recorded by an ambulatory blood pressure monitor attached to their arm for 36 hrs before and after the treatment. They were given 1, 2 or 5 g of NTW-03 or placebo for 6 days followed by a washout period of 5 days. This process was repeated on the other arm. The subjects were asked not to consume caffeine, tobacco or any other medications during the study period. The change in day time and night time BP were calculated from the 36 hrs recording before and after the treatment.
1 g NTW-03 had no effect on any of the groups, whereas 2 g NTW-03 decreased daytime systolic BP and daytime diastolic BP of mild hypertensive subjects compared to baseline BP and placebo. However, 2 g NTW-03 had no effect on the normal BP or normal-high BP groups. A similar effect was observed with 5 g NTW-03 on mild hypertension subjects, except the changes were observed only for the night time BP. Since night time BP was recorded less frequently, the authors note that this data may be less reliable. There are studies that show that people with decreased blood pressure during sleep are vulnerable to cardiovascular events and mortality. No clear dose-response relationship was observed, so more studies are needed to determine changes in daytime and nighttime BP.
Written By: Mandira Manandhar, PhD